Bendeka bendamustine regulatory update

FDA approved an NDA from Eagle for Bendeka bendamustine to treat chronic lymphocytic leukemia (CLL) and indolent B cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within 6 months of tr...